Details about Nancy Devlin
Access statistics for papers by Nancy Devlin.
Last updated 2022-11-06. Update your information in the RePEc Author Service.
Short-id: pde347
Jump to Journal Articles
Working Papers
2016
- “New Age” Decision Making in HTA: Is It Applicable in Asia?
Briefing, Office of Health Economics
2013
- Methods for the estimation of the NICE cost effectiveness threshold
Working Papers, Centre for Health Economics, University of York View citations (49)
- The influence of cost-effectiveness and other factors on NICE decisions
Working Papers, Centre for Health Economics, University of York View citations (8)
See also Journal Article The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (21) (2015)
2012
- Analysing Hospital Variation in Health Outcome at the Level of EQ-5D Dimensions
Working Papers, Centre for Health Economics, University of York View citations (1)
- Time to tweak the TTO. But how?
MPRA Paper, University Library of Munich, Germany View citations (1)
2011
- Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes
Working Papers, Centre for Health Economics, University of York View citations (5)
See also Journal Article TRULY INEFFICIENT OR PROVIDING BETTER QUALITY OF CARE? ANALYSING THE RELATIONSHIP BETWEEN RISK‐ADJUSTED HOSPITAL COSTS AND PATIENTS' HEALTH OUTCOMES, Health Economics, John Wiley & Sons, Ltd. (2013) View citations (18) (2013)
2000
- Allocating Vote: Health — ‘Needs Assessment’ and an Economics-Based Approach
Treasury Working Paper Series, New Zealand Treasury
- The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs
Working Papers, Centre for Health Economics, University of York View citations (6)
Journal Articles
2022
- A Comparison of PROPr and EQ-5D-5L Value Sets
PharmacoEconomics, 2022, 40, (3), 297-307 View citations (1)
- Correction to: Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
PharmacoEconomics, 2022, 40, (4), 477-478 View citations (4)
- How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents
PharmacoEconomics, 2022, 40, (2), 157-182
- Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review
PharmacoEconomics, 2022, 40, (7), 663-698 View citations (2)
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
Applied Health Economics and Health Policy, 2022, 20, (5), 651-667 View citations (1)
- Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures
PharmacoEconomics, 2022, 40, (4), 379-431 View citations (4)
2021
- Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
Applied Health Economics and Health Policy, 2021, 19, (5), 635-644 View citations (3)
- EQ-5D-5L Health-State Values for the Mexican Population
Applied Health Economics and Health Policy, 2021, 19, (6), 905-914 View citations (1)
- Giving a Voice to Marginalised Groups for Health Care Decision Making
The Patient: Patient-Centered Outcomes Research, 2021, 14, (1), 5-10
- Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia
Health Economics, 2021, 30, (8), 1950-1977 View citations (1)
- Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
Medical Decision Making, 2021, 41, (5), 584-596
- What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the development of the EQ-HWB?
The European Journal of Health Economics, 2021, 22, (7), 1067-1081 View citations (3)
2020
- A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’
Social Science & Medicine, 2020, 246, (C) View citations (7)
- An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values
The European Journal of Health Economics, 2020, 21, (7), 1091-1103 View citations (5)
- Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland
Health Policy, 2020, 124, (6), 639-646 View citations (1)
- International Valuation Protocol for the EQ-5D-Y-3L
PharmacoEconomics, 2020, 38, (7), 653-663 View citations (7)
- Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?
PharmacoEconomics, 2020, 38, (4), 325-340 View citations (12)
- The impact of price transparency on consumers and providers: A scoping review
Health Policy, 2020, 124, (8), 819-825 View citations (8)
2019
- A new method for valuing health: directly eliciting personal utility functions
The European Journal of Health Economics, 2019, 20, (2), 257-270 View citations (11)
- All Male Panels and Other Diversity Considerations for ISPOR
PharmacoEconomics - Open, 2019, 3, (3), 423-426
- Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments
The European Journal of Health Economics, 2019, 20, (1), 99-105 View citations (1)
2018
- 3L, 5L, What the L? A NICE Conundrum
PharmacoEconomics, 2018, 36, (6), 637-640 View citations (2)
- Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
PharmacoEconomics - Open, 2018, 2, (2), 153-163 View citations (1)
- Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
PharmacoEconomics, 2018, 36, (6), 699-713 View citations (7)
- Correction to: 3L, 5L, What the L? A NICE Conundrum
PharmacoEconomics, 2018, 36, (6), 729-729 View citations (2)
- Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
PharmacoEconomics, 2018, 36, (6), 727-727 View citations (1)
- New methods for modelling EQ‐5D‐5L value sets: An application to English data
Health Economics, 2018, 27, (1), 23-38 View citations (12)
- Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L
PharmacoEconomics, 2018, 36, (11), 1345-1353 View citations (7)
- Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment
The European Journal of Health Economics, 2018, 19, (4), 595-605 View citations (3)
- Valuing health‐related quality of life: An EQ‐5D‐5L value set for England
Health Economics, 2018, 27, (1), 7-22 View citations (33)
2017
- A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
Applied Health Economics and Health Policy, 2017, 15, (4), 469-477 View citations (4)
- Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial
The Patient: Patient-Centered Outcomes Research, 2017, 10, (6), 677-686
- EQ-5D and the EuroQol Group: Past, Present and Future
Applied Health Economics and Health Policy, 2017, 15, (2), 127-137 View citations (43)
- Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale
The European Journal of Health Economics, 2017, 18, (8), 967-977 View citations (2)
2016
- What Determines the Shape of an EQ-5D Index Distribution?
Medical Decision Making, 2016, 36, (8), 941-951 View citations (2)
2015
- A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
PharmacoEconomics, 2015, 33, (8), 867-877 View citations (6)
- INTER‐PROVIDER COMPARISON OF PATIENT‐REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX
Health Economics, 2015, 24, (1), 41-54 View citations (2)
- Local health care expenditure plans and their opportunity costs
Health Policy, 2015, 119, (9), 1237-1244 View citations (6)
- The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions
Health Economics, 2015, 24, (10), 1256-1271 View citations (21)
See also Working Paper The influence of cost-effectiveness and other factors on NICE decisions, Working Papers (2013) View citations (8) (2013)
2013
- A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO
Health Economics, 2013, 22, (5), 517-532 View citations (26)
- Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions
Medical Decision Making, 2013, 33, (6), 804-818 View citations (8)
- Lead versus lag-time trade-off variants: does it make any difference?
The European Journal of Health Economics, 2013, 14, (1), 25-31 View citations (2)
- One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands
The European Journal of Health Economics, 2013, 14, (1), 65-73 View citations (5)
- Operationalizing Value-Based Pricing of Medicines
PharmacoEconomics, 2013, 31, (1), 1-10 View citations (15)
- TRULY INEFFICIENT OR PROVIDING BETTER QUALITY OF CARE? ANALYSING THE RELATIONSHIP BETWEEN RISK‐ADJUSTED HOSPITAL COSTS AND PATIENTS' HEALTH OUTCOMES
Health Economics, 2013, 22, (8), 931-947 View citations (18)
See also Working Paper Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes, Working Papers (2011) View citations (5) (2011)
- The development of new research methods for the valuation of EQ-5D-5L
The European Journal of Health Economics, 2013, 14, (1), 1-3 View citations (12)
- The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework
The European Journal of Health Economics, 2013, 14, (1), 15-24 View citations (4)
- Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
The European Journal of Health Economics, 2013, 14, (1), 43-51 View citations (4)
2011
- A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach
Health Economics, 2011, 20, (3), 348-361 View citations (38)
2010
- An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions
PharmacoEconomics, 2010, 28, (11), 987-993 View citations (2)
- Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data
Health Economics, 2010, 19, (8), 886-905 View citations (11)
- Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review
Medical Decision Making, 2010, 30, (5), 610-619 View citations (15)
- Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?
Medical Decision Making, 2010, 30, (5), 556-565 View citations (7)
2009
- A note on the nature of utility in time and health and implications for cost utility analysis
Social Science & Medicine, 2009, 68, (2), 362-367 View citations (8)
- Identifying the impact of government targets on waiting times in the NHS
Health Care Management Science, 2009, 12, (1), 1-10 View citations (31)
- Searching for cost effectiveness thresholds in the NHS
Health Policy, 2009, 91, (3), 239-245 View citations (30)
2007
- ‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder
Health Economics, 2007, 16, (6), 649-651
2006
- "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making
Health Policy, 2006, 77, (3), 352-367 View citations (10)
- A theoretical framework for TTO valuations of health
Health Economics, 2006, 15, (10), 1149-1154 View citations (10)
- Is there a case for using visual analogue scale valuations in cost‐utility analysis?
Health Economics, 2006, 15, (7), 653-664 View citations (33)
2005
- A ‘new and improved’ EQ-5D valuation questionnaire?
The European Journal of Health Economics, 2005, 6, (1), 73-82 View citations (3)
- Continuity through change: The rhetoric and reality of health reform in New Zealand
Social Science & Medicine, 2005, 61, (2), 253-262 View citations (9)
2004
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis
Health Economics, 2004, 13, (5), 437-452 View citations (115)
- Getting Health Economics into Practice, Edited by David Kernick. Radcliffe Medical Press, Oxford, 2002. No. of pages: 358. ISBN 1‐85775‐575‐8
Health Economics, 2004, 13, (5), 499-500
2003
- Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs
Health Economics, 2003, 12, (7), 529-544 View citations (25)
2002
- The Purchasing of Health Care by Primary Care Organisations. An evaluation and Guide to Future Policy, by N. Mays, S. Wyke, G. Malbon, N. Goodwin. Open University Press, Buckingham and Philadelphia, 2001. No. of pages: 320. ISBN 0‐335‐20900‐9
Health Economics, 2002, 11, (6), 567-568
2001
- Health care spending and economic output: Granger causality
Applied Economics Letters, 2001, 8, (8), 561-564 View citations (57)
1999
- The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule
Social Science & Medicine, 1999, 49, (6), 763-779 View citations (3)
1996
- The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand
Health Policy, 1996, 38, (2), 101-115 View citations (8)
1995
- Comment: Financing New Zealand’s Tertiary Education: How Much Subsidy?
Agenda - A Journal of Policy Analysis and Reform, 1995, 2, (2), 223-225
1994
- The effects of denturism: New Zealand dentists' response to competition
American Journal of Public Health, 1994, 84, (10), 1675-1677
|
The links between different versions of a paper are constructed automatically by matching on the titles.
Please contact if a link is incorrect.
Use this form
to add links between versions where the titles do not match.
|